Skip to content
Menu

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.

Read at benzinga.com

← All stock news